Citigroup
BLRX

Citigroup’s BioLineRX BLRX Stock Holding History

Citigroup’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3 Sell
1
-1,727
-100% -$5.01K ﹤0.01% 5633
2026
Q1 		$3.99K Sell
1,728
-310
-15% -$870 ﹤0.01% 5306
2025
Q4 		$5.81K Buy
+2,038
New +$7.04K ﹤0.01% 5202
2025
Q3 		– Sell
-4,005
Closed -$18.3K – 6095
2025
Q2 		$18.3K Buy
+4,005
New +$14.8K ﹤0.01% 5097
2025
Q1 		– Sell
-783
Closed -$6.66K – 5602
2024
Q4 		$6.66K Buy
+783
New +$11.6K ﹤0.01% 5428
2022
Q3 		– Sell
-85
Closed -$4K – 5842
2022
Q2 		$4K Buy
+85
New +$4.73K ﹤0.01% 5662
2016
Q2 		– Sell
-2
Closed -$1K – 7084
2016
Q1 		$1K Buy
+2
New +$1.26K ﹤0.01% 7277
2015
Q2 		– Sell
-8
Closed -$11K – 7520
2015
Q1 		$11K Buy
+8
New +$9.85K ﹤0.01% 6410
2014
Q4 		– Hold
0
– – – 7110
2014
Q2 		– Sell
-1
Closed -$2K – 7113
2014
Q1 		$2K Buy
+1
New +$1.64K ﹤0.01% 6768
2013
Q4 		– Sell
-1
Closed -$1.61K – 6980
2013
Q3 		$1K Hold
1
– – ﹤0.01% 6651
2013
Q2 		$1K Buy
+1
New +$1.04K ﹤0.01% 6607

Other funds holding BLRX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Citigroup's BLRX Position: Q2 2026 in Review

Citigroup reduced its BioLineRX (BLRX) stake by 100% in Q2 2026, selling an estimated $5.01K and leaving 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #5633.

Citigroup first reported a position in BLRX in Q2 2013 and has held it in 11 quarters since. The position peaked at $18.3K in Q2 2025. 9 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

  • Citigroup held 1 share of BioLineRX worth $3 as of Q2 2026.
  • Citigroup sold 1,727 BioLineRX shares in Q2 2026, an estimated $5.01K.
  • BioLineRX made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5633 holding.
  • Citigroup first reported a position in BioLineRX in Q2 2013 and has held it in 11 quarters since.
  • Citigroup's BioLineRX position peaked at $18.3K in Q2 2025.
  • 9 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.